Catheter Precision Announces Successful LockeT Launch in South Africa
Rhea-AI Summary
Catheter Precision (NYSE:VTAK) announced rapid commercial uptake of its LockeT closure device in South Africa on Nov 20, 2025. With distributor HLC Medical and Dr. Heather Henry-Lines, LockeT was implemented in five hospitals within two months; three hospitals use LockeT daily and two use it routinely. Two additional hospitals are awaiting internal approvals. All five hospitals have placed reorders through the distributor. Management highlighted LockeT as cost effective, workflow-improving, and supportive of rapid hemostasis enabling same-day discharge.
Positive
- 5 hospitals implemented within two months
- 3 hospitals using LockeT daily
- All 5 hospitals placed reorders via distributor
- Device described as cost effective and workflow improving
Negative
- Adoption limited to five hospitals to date
- 2 hospitals still awaiting internal approvals
News Market Reaction 2 Alerts
On the day this news was published, VTAK declined 9.88%, reflecting a notable negative market reaction. Argus tracked a peak move of +12.5% during that session. Argus tracked a trough of -5.6% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $287K from the company's valuation, bringing the market cap to $3M at that time. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
FORT MILL, S.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announces the rapid commercial uptake of its LockeT closure device in South Africa.
With the assistance of local distributor, HLC Medical and Dr. Heather Henry-Lines, LockeT was successfully implemented in five hospitals within two months. Three of these hospitals are using LockeT daily and the other two hospitals are using LockeT routinely. In addition, two additional hospitals are awaiting internal approvals. All five hospitals have placed reorders of LockeT via VTAK’s distributor.
“The rapid uptake of LockeT in such a short time frame underscores the importance of LockeT in emerging markets”, said Fatih Ayoglu, European Sales Manager at Catheter Precision. He continued, “Emerging markets are conscious of cost, but also require that the products improve workflow while improving and expediting patient care. LockeT fits in nicely because it is cost effective, improves workflow and assists in rapid hemostasis enabling same day discharge.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
What did Catheter Precision (VTAK) announce on November 20, 2025 about LockeT in South Africa?
How many South African hospitals use LockeT daily as of Nov 20, 2025?
What does the LockeT reorder activity mean for VTAK distribution in South Africa?
Are more South African hospitals expected to adopt LockeT after Nov 20, 2025?
What clinical or operational benefits did Catheter Precision cite for LockeT (VTAK)?
